iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

Press/Media

Period30 Dec 2020

Media coverage

1

Media coverage

  • TitleiCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
    Media name/outletICrowdNewswire (English)
    Country/TerritoryUnited States
    Date30/12/20
    PersonsMichael Klein